Description
RP1- Granzyme B is a rabbit polyclonal antibody made to the chymotrypsin-like protease granzyme B. The antibody is made to a synthetic peptide based on the aminoterminal end of mature human granzyme B. The antibody has been peptide-affinity purified, concentrated to 1.0 mg/ml, with the addition of 0.05% sodium azide as preservative and 50% glycerol as cryoprotectant.
Use
Granzyme-B, also known as Granzyme-2, Cytotoxic T-Lymphocyte Proteinase 2, SECT, Lymphocyte protease, Cathepsin G-like protease and CTSGL1, is a chymotrypsin-like serine proteinase produced by cytotoxic lymphocytes. Similar to chymase and cathepsin G (with 57% and 52% identity at the amino acid level respectively), granzyme-B is a member of the PA clan of serine proteinases, in the S1A family. These chymotrypsin-like serine proteinases have a catalytic triad of HDS, with the catalytic serine held in the GDSGGP motif. Granzymne B lacks the conserved disulfide bond found near the active site in chymotrypsin, which gives granzyme B a different substrate range than chymotrypsin. Granzyme B is best known for the ability to induce apoptosis in target cells by proteolytically cleaving and activating a caspase cascade. Granzyme B is secreted from the cytotoxic T-lymphocytes bound to serglycan, and appears to bind to target cells via the mannose-6-phosphate receptor. Granzyme B has also been implicated in cartilage degradation, where it is able to cleave aggrecan, and is thought to be over expressed in rheumatoid arthritis. Pro-Granzyme-B is activated by cleavage of a 2 amino acid propeptide domain. The human granzyme B sequence encodes a protein of 247 amino acids, with predicted mass of 27.7 kDa and a pI of 9.81. Glycosylation adds 2 kDa or so to the apparent mass, and the basic pI encourages association with GAGs and heparin. A recommended starting concentration for Western blots is 1:1,000 when using colorimetric substrates such as BCIP/NBT, and 1:5,000 for chemiluminescent substrates. Higher concentrations of antibody may be needed for samples from more distantly related species. FOR RESEARCH USE ONLY; NOT FOR USE IN HUMANS.
Storage
The undiluted antibody solution is stable for 12 months at -20C.
Description
RP2- Granzyme B is a rabbit polyclonal antibody made to the chymotrypsin-like protease granzyme B. The antibody is made to a synthetic peptide based on the catalytic domain of human granzyme B, after the catalytic histidine residue. The antibody has been peptide-affinity purified, concentrated to 1.0 mg/ml, with the addition of 0.05% sodium azide as preservative and 50% glycerol as cryoprotectant.
Use
Granzyme-B, also known as Granzyme-2, Cytotoxic T-Lymphocyte Proteinase 2, SECT, Lymphocyte protease, Cathepsin G-like protease and CTSGL1, is a chymotrypsin-like serine proteinase produced by cytotoxic lymphocytes. Similar to chymase and cathepsin G (with 57% and 52% identity at the amino acid level respectively), granzyme-B is a member of the PA clan of serine proteinases, in the S1A family. These chymotrypsin-like serine proteinases have a catalytic triad of HDS, with the catalytic serine held in the GDSGGP motif. Granzymne B lacks the conserved disulfide bond found near the active site in chymotrypsin, which gives granzyme B a different substrate range than chymotrypsin. Granzyme B is best known for the ability to induce apoptosis in target cells by proteolytically cleaving and activating a caspase cascade. Granzyme B is secreted from the cytotoxic T-lymphocytes bound to serglycan, and appears to bind to target cells via the mannose-6-phosphate receptor. Granzyme B has also been implicated in cartilage degradation, where it is able to cleave aggrecan, and is thought to be over expressed in rheumatoid arthritis. Pro-Granzyme-B is activated by cleavage of a 2 amino acid propeptide domain. The human granzyme B sequence encodes a protein of 247 amino acids, with predicted mass of 27.7 kDa and a pI of 9.81. Glycosylation adds 2 kDa or so to the apparent mass, and the basic pI encourages association with GAGs and heparin. A recommended starting concentration for Western blots is 1:1,000 when using colorimetric substrates such as BCIP/NBT, and 1:5,000 for chemiluminescent substrates. Higher concentrations of antibody may be needed for samples from more distantly related species. FOR RESEARCH USE ONLY; NOT FOR USE IN HUMANS.
Storage
The undiluted antibody solution is stable for 12 months at -20C.
Description
RP3- Granzyme B is a rabbit polyclonal antibody made to the chymotrypsin-like protease granzyme B. The antibody is made to a synthetic peptide based on the catalytic domain of human granzyme B, after the catalytic aspartic acid residue. The antibody has been peptide-affinity purified, concentrated to 1.0 mg/ml, with the addition of 0.05% sodium azide as preservative and 50% glycerol as cryoprotectant.
Use
Granzyme-B, also known as Granzyme-2, Cytotoxic T-Lymphocyte Proteinase 2, SECT, Lymphocyte protease, Cathepsin G-like protease and CTSGL1, is a chymotrypsin-like serine proteinase produced by cytotoxic lymphocytes. Similar to chymase and cathepsin G (with 57% and 52% identity at the amino acid level respectively), granzyme-B is a member of the PA clan of serine proteinases, in the S1A family. These chymotrypsin-like serine proteinases have a catalytic triad of HDS, with the catalytic serine held in the GDSGGP motif. Granzymne B lacks the conserved disulfide bond found near the active site in chymotrypsin, which gives granzyme B a different substrate range than chymotrypsin. Granzyme B is best known for the ability to induce apoptosis in target cells by proteolytically cleaving and activating a caspase cascade. Granzyme B is secreted from the cytotoxic T-lymphocytes bound to serglycan, and appears to bind to target cells via the mannose-6-phosphate receptor. Granzyme B has also been implicated in cartilage degradation, where it is able to cleave aggrecan, and is thought to be over expressed in rheumatoid arthritis. Pro-Granzyme-B is activated by cleavage of a 2 amino acid propeptide domain. The human granzyme B sequence encodes a protein of 247 amino acids, with predicted mass of 27.7 kDa and a pI of 9.81. Glycosylation adds 2 kDa or so to the apparent mass, and the basic pI encourages association with GAGs and heparin. A recommended starting concentration for Western blots is 1:1,000 when using colorimetric substrates such as BCIP/NBT, and 1:5,000 for chemiluminescent substrates. Higher concentrations of antibody may be needed for samples from more distantly related species. FOR RESEARCH USE ONLY; NOT FOR USE IN HUMANS.
Storage
The undiluted antibody solution is stable for 12 months at -20C.